68709-74-0

Downstream Products

• 169701-56-8 (5S)-6-phenyl-5-[(tert-butyloxycarbonyl)amino]-4-oxo-hexanoyl-L-phenylalanine methyl ester 
• 74075-32-4 (5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenyl-hexanoyl-L-proline benzyl ester 
• 74075-33-5 SRI-20 
• 910316-86-8 (5S)-6-phenyl-5-[(tert-butyloxycarbonyl)amino]-4-oxo-hexanoyl-L-tryptophan methyl ester 
• 910316-84-6 (5S)-6-phenyl-5-[(tert-butyloxycarbonyl)amino]-4-oxo-hexanoyl-L-proline benzyl ester 
• 68709-76-2 5(S)-<(butyloxycarbonyl)amino>-6-phenyl-4-oxohexanoic acid 

Relevant academic research and scientific papers

Angiotensin I-converting enzyme (ace) inhibitors

This invention relates to a process for the synthesis of ketomethylene derivatives of the tripeptide Phe-Gly-Pro (“keto-ACE”, compound 5a) and analogues thereof. The synthesis process proceeds via an α,β-unsaturated keto intermediate. A key feature of the process involves a Horner-Emmons olefination of the, -unsaturated keto-phosphonate with ethyl glyoxylate. Keto-ACE analogues produced by the process of the invention display C-domain selectivity.

Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors

Novel analogues of the angiotensin I-converting enzyme (ACE) inhibitor keto-ACE were synthesized via a facile Horner-Emmons olefination of a phosphonoketone precursor with ethyl glyoxylate. Introduction of a bulky aromatic tryptophan at the P2